These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12755849)

  • 1. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment.
    Haro JM; Edgell ET; Frewer P; Alonso J; Jones PB;
    Acta Psychiatr Scand Suppl; 2003; (416):7-15. PubMed ID: 12755849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The European schizophrenia outpatient health outcomes (SOHO) study: baseline findings of the Spanish sample].
    Ciudad A; Prieto L; Olivares JM; Montejo AL; Ros S; Novick D;
    Actas Esp Psiquiatr; 2004; 32(4):227-35. PubMed ID: 15232752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment.
    Haro JM; Edgell ET; Jones PB; Alonso J; Gavart S; Gregor KJ; Wright P; Knapp M;
    Acta Psychiatr Scand; 2003 Mar; 107(3):222-32. PubMed ID: 12580830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
    Knapp M; Windmeijer F; Brown J; Kontodimas S; Tzivelekis S; Haro JM; Ratcliffe M; Hong J; Novick D;
    Pharmacoeconomics; 2008; 26(4):341-58. PubMed ID: 18370568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients.
    Karagianis J; Novick D; Pecenak J; Haro JM; Dossenbach M; Treuer T; Montgomery W; Walton R; Lowry AJ
    Int J Clin Pract; 2009 Nov; 63(11):1578-88. PubMed ID: 19780867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost evaluation of risperidone compared with olanzapine.
    Byerly MJ; Weber M; Brooks D; Casey SB; Elliot S; Hawkins J
    Psychiatr Serv; 2003 May; 54(5):742-4. PubMed ID: 12719509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.
    Revicki DA
    Schizophr Res; 1999 Mar; 35 Suppl():S101-9. PubMed ID: 10190231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Service use and costs of treating schizophrenia with atypical antipsychotics.
    Lewis M; McCrone P; Frangou S
    J Clin Psychiatry; 2001 Oct; 62(10):749-56. PubMed ID: 11816863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.
    Haro JM; Salvador-Carulla L
    CNS Drugs; 2006; 20(4):293-301. PubMed ID: 16599647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.
    Zhao Z
    Manag Care Interface; 2002 Feb; 15(2):75-81. PubMed ID: 11875967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching antipsychotic medications.
    Weiden PJ; Aquila R; Dalheim L; Standard JM
    J Clin Psychiatry; 1997; 58 Suppl 10():63-72. PubMed ID: 9265919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
    Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
    J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
    Hamilton SH; Revicki DA; Edgell ET; Genduso LA; Tollefson G
    Pharmacoeconomics; 1999 May; 15(5):469-80. PubMed ID: 10537964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine and risperidone.
    Love RC; Kelly DL
    Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
    [No Abstract]   [Full Text] [Related]  

  • 17. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluations of olanzapine and risperidone.
    Shaw JW
    Am J Health Syst Pharm; 2002 Jul; 59(14):1366-75. PubMed ID: 12132564
    [No Abstract]   [Full Text] [Related]  

  • 20. [Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].
    Le Pen C; Lilliu H; Allicar MP; Olivier V; Gregor KJ
    Encephale; 1999; 25(4):281-6. PubMed ID: 10546082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.